Personalized paroxysmal atrial fibrillation ablation by tailoring ablation index to the left atrial wall thickness: the 'Ablate by-LAW' single-centre study-a pilot study.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
02 03 2022
Historique:
received: 17 12 2020
pubmed: 5 9 2021
medline: 1 4 2022
entrez: 4 9 2021
Statut: ppublish

Résumé

To determine if adapting the ablation index (AI) to the left atrial wall thickness (LAWT), which is a determinant of lesion transmurality, is feasible, effective, and safe during paroxysmal atrial fibrillation (PAF) ablation. Consecutive patients referred for PAF first ablation. Left atrial wall thickness three-dimensional maps were obtained from multidetector computed tomography and integrated into the CARTO navigation system. Left atrial wall thickness was categorized into 1 mm layers and AI was titrated to the LAWT. The ablation line was personalized to avoid thicker regions. Primary endpoints were acute efficacy and safety, and freedom from atrial fibrillation (AF) recurrences. Follow-up (FU) was scheduled at 1, 3, 6, and every 6 months thereafter. Ninety patients [60 (67%) male, age 58 ± 13 years] were included. Mean LAWT was 1.25 ± 0.62 mm. Mean AI was 366 ± 26 on the right pulmonary veins with a first-pass isolation in 84 (93%) patients and 380 ± 42 on the left pulmonary veins with first-pass in 87 (97%). Procedure time was 59 min (49-66); radiofrequency (RF) time 14 min (12.5-16); and fluoroscopy time 0.7 min (0.5-1.4). No major complication occurred. Eighty-four out of 90 (93.3%) patients were free of recurrence after a mean FU of 16 ± 4 months. Personalized AF ablation, adapting the AI to LAWT allowed pulmonary vein isolation with low RF delivery, fluoroscopy, and procedure time while obtaining a high rate of first-pass isolation, in this patient population. Freedom from AF recurrences was as high as in more demanding ablation protocols. A multicentre trial is ongoing to evaluate reproducibility of these results.

Identifiants

pubmed: 34480548
pii: 6364095
doi: 10.1093/europace/euab216
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

390-399

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Cheryl Teres (C)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

David Soto-Iglesias (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Diego Penela (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Beatriz Jáuregui (B)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Augusto Ordoñez (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Alfredo Chauca (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Jose Miguel Carreño (JM)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Claudia Scherer (C)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Rodolfo San Antonio (R)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Marina Huguet (M)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Albert Roque (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Carlos Ramírez (C)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Guillermo Oller (G)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Agustí Jornet (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Jordi Palet (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

David Santana (D)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Alejandro Panaro (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Giuliana Maldonado (G)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Gustavo de Leon (G)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Gustavo Jiménez (G)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Arturo Evangelista (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Julio Carballo (J)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

José-Tomás Ortíz-Pérez (JT)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Antonio Berruezo (A)

Heart Institute, Teknon Medical Center, C/Vilana, 12, 08022 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH